A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer
A phase 3 trial of Darolutamide in prostate cancer, run by Bayer, active and no longer recruiting.
Overview
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies is a phase 3 interventional study registered as NCT05794906 by Bayer, with 985 participants enrolled, started 2023-04-03 and due to reach its primary completion in 2027-07-30. Interventions recorded: Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT. Conditions listed: Biochemically Recurrent Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi
Shares Darolutamide, Bayer, Prostate cancer.
- TrialStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Shares Darolutamide, Bayer.
- TrialA Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Shares Darolutamide, Prostate cancer.
- TrialTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
Shares Darolutamide, Prostate cancer.
- TrialA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Shares Darolutamide, Prostate cancer.
- TrialGedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Shares Darolutamide, Prostate cancer.
- TrialARASENS
Shares Darolutamide, Prostate cancer.
- TrialStudy of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Shares Darolutamide, Prostate cancer.